Navigation Links
PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
Date:5/27/2009

BOSTON, May 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced it has reached a milestone in managing oncology-based clinical trials over the last five years, which have involved over 175,000 patients in hundreds of programs across 80 countries. PAREXEL will be marking this milestone during the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 - June 2, 2009 in Orlando, Florida. PAREXEL's hematology and oncology experts will be available during the ASCO meeting at Booth #1980 to discuss their capabilities to support the successful development of novel cancer treatments.

"Significant advances in targeted therapies for cancer have generated more competition for patient populations. To meet industry demand for conducting cancer trials across a broad range of indications, PAREXEL continues to leverage our global footprint and ability to manage complex programs on a worldwide scale to help biopharmaceutical companies access diverse patient populations, navigate regulatory issues, and identify effective investigators," said Mark A. Goldberg, M.D., Chief Operating Officer, PAREXEL International.

"With approximately 10 million people diagnosed with cancer each year worldwide, PAREXEL works with biopharmaceutical companies toward the goals of improving the development success rate for oncology drugs and getting treatments to patients sooner," said Denis R. Miller, M.D., Senior Medical Director, Clinical Research Services, PAREXEL. "Our global team of hematology and oncology experts helps clients advance important innovations through our understanding of unmet medical needs, the standards of available cancer care worldwide, and how new anticancer agents will be positioned in the treatment of patients, from the earliest phases of clinical development through the approval process and into post-marketing."

PAREXEL has experience across a broad range of cancer indications as well as all classes of therapeutics including cytotoxics, biologics, targeted therapies, immunotherapies, vaccine therapies, and supportive treatments, such as blood products, growth factors, antiemetics, and analgesics. PAREXEL's Hematology/Oncology Therapeutic Area Team offers expertise to help clients with every facet of drug development, including protocol review, safety assessment, clinical development, medical imaging, technology integration, regulatory affairs, and product lifecycle management. Comprehensive services provided by the team include the planning, design, and management of feasibility studies, Phase I - IV trials, and post-marketing studies as well as site selection, patient recruitment, data analysis, non-clinical evaluation, and IND/NDA submissions. PAREXEL leverages the experience and relationships its experts have with leading cancer centers and key opinion leaders in its ongoing collaborative efforts.

PAREXEL applies a proven, therapeutically focused expertise methodology to clinical development programs across a broad range of areas. For more information about PAREXEL's in-depth expertise in the oncology, central nervous system (CNS), cardiovascular, infectious disease therapeutic areas, as well as a broad range of other therapeutic areas, visit: http://www.parexel.com/clinical_research/therapeutic_expertise.html.

Information about the ASCO Annual Meeting can be found at: http://www.asco.org/annualmeeting.

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 69 locations throughout 52 countries around the world, and has over 9,400 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 as filed with the SEC on May 8, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Contacts:
    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409
    Email: Jennifer.Baird@PAREXEL.com

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817
    Email: rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
7. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
8. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
9. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
10. Genmab Reaches Milestone in Ofatumumab Collaboration
11. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  Specialty Silicone Fabricators ... that shows how a cleanroom works. The free ... about science and technology. ... a technology company, SSF enthusiastically supports the Science, ... educators foster the next generation of innovators. We ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with Melanoma ... United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well as residents ... on skin safety and health now and in the future. , The dermatology-specific awareness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Dr. Elyson and Dr. Assili, ... at their office. Wisdom tooth removal, a common dental procedure, is performed for many ... are improperly erupted, resulting in risks of complications. By providing wisdom tooth removal surgery ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... foundational nutrients that supports cellular and metabolic health. This synergistic combination of omega-3 ... free-form curcumin, along with 150 mg of reduced glutathione and 200 mg of ...
(Date:5/4/2016)... NC (PRWEB) , ... May 04, 2016 , ... Francesca ... N.C., changed her life forever with a same-day LASIK procedure at Christenbury ... poor eyesight. Dr. Jonathan Christenbury performed her surgery the same day as her in-office ...
(Date:5/4/2016)... ... 04, 2016 , ... Pharmacy Times , the leading ... chosen as the Pharmaceutical News Provider of the Year in the inaugural ... work and dedication of community members who strive to make the pharmaceutical purchasing ...
Breaking Medicine News(10 mins):